Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan.
Department of Public Health, Hyogo College of Medicine, Nishinomiya, Japan.
J Clin Pharm Ther. 2020 Aug;45(4):682-690. doi: 10.1111/jcpt.13144. Epub 2020 Apr 17.
Vancomycin therapeutic guidelines suggest a loading dose of 25-30 mg/kg for seriously ill patients. However, high-quality data to guide the use of loading doses are lacking. We aimed to evaluate whether a loading dose (a) achieved a target trough concentration at steady state and (b) improved early clinical response.
Patients with an estimated glomerular filtration rate ≥ 90 mL/min/1.73 m were included. A loading dose of 25 mg/kg vancomycin followed by 15 mg/kg twice daily was compared with traditional dosing. A C sample was obtained before the fifth dose. An early clinical response 48-72 hours after the start of therapy and clinical success at end of therapy (EOT) was evaluated in patients with methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative Staphylococci or Enterococcus faecium.
There was no significant difference in C between the regimen with and without a loading dose (median: 10.4 and 10.2 µg/mL, P = .54). Proportions of patients achieving 10-20 and 15-20 µg/mL were 56.9% and 5.6%, respectively, in patients with a loading dose. Although there was no significant difference in success rate at EOT between groups, a loading dose was associated with increased early clinical response for all infections (adjusted odds ratio [OR]: 4.588, 95% confidence interval [CI]: 1.373-15.330) and MRSA infections (OR: 12.065, 95% CI: 1.821-79.959). Study limitations included no C measurements within 24 hours and the inclusion of less critically ill patients.
A loading dose of 25 mg/kg followed by 15 mg/kg twice daily did not achieve the optimal Cmin at steady state in patients with normal renal function. However, more early clinical responses were obtained with a loading dose compared with traditional dosing, possibly because of a prompt albeit temporary achievement of a more effective concentration.
万古霉素治疗指南建议对重病患者给予 25-30mg/kg 的负荷剂量。然而,缺乏高质量的数据来指导负荷剂量的使用。我们旨在评估负荷剂量(a)是否达到稳态时的目标谷浓度,以及(b)是否改善早期临床反应。
纳入估计肾小球滤过率≥90mL/min/1.73m2的患者。与传统剂量相比,给予 25mg/kg 万古霉素负荷剂量,然后每日两次给予 15mg/kg。在第五剂前采集 C 样本。在开始治疗后 48-72 小时评估甲氧西林耐药金黄色葡萄球菌(MRSA)、甲氧西林耐药凝固酶阴性葡萄球菌或屎肠球菌患者的早期临床反应和治疗结束时的临床疗效(EOT)。
有和没有负荷剂量的方案之间 C 没有显著差异(中位数:10.4 和 10.2μg/mL,P=0.54)。有负荷剂量的患者中,达到 10-20μg/mL 和 15-20μg/mL 的比例分别为 56.9%和 5.6%。尽管两组在 EOT 时的成功率没有显著差异,但负荷剂量与所有感染(调整后的优势比[OR]:4.588,95%置信区间[CI]:1.373-15.330)和 MRSA 感染(OR:12.065,95%CI:1.821-79.959)的早期临床反应增加有关。研究局限性包括在 24 小时内没有 C 测量值,以及纳入的病情较轻的患者较少。
在肾功能正常的患者中,给予 25mg/kg 负荷剂量,然后每日两次给予 15mg/kg,无法在稳态时达到最佳 Cmin。然而,与传统剂量相比,负荷剂量可获得更多的早期临床反应,这可能是因为更快但暂时达到了更有效的浓度。